Martínez-Gestoso, Sandra
García-Sanz, María-Teresa
Carreira, José-Martín
Salgado, Francisco-Javier
Calvo-Álvarez, Uxío
Doval-Oubiña, Liliana
Camba-Matos, Sandra
Peleteiro-Pedraza, Lorena
González-Pérez, Miguel-Angel
Penela-Penela, Pedro
Vilas-Iglesias, Andrés
González-Barcala, Francisco-Javier
Article History
Received: 30 January 2022
Accepted: 31 March 2022
First Online: 29 April 2022
Change Date: 30 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12890-022-01999-9
Declarations
:
: This study was performed in accordance with relevant guidelines and regulations. Original and observational study approved by the Galician Ethical Committee (Registry Code 2016/460), Spain. All patients admitted included in the study signed the informed consent form.
: Not applicable.
: Gonzalez-Barcala Francisco-Javier has received speaker fees, consulting fees or research grants from ALK, Astra-Zeneca, Bial, Boehringer-Ingelheim, Chiesi, Gebro Pharma, GlaxoSmithKline, Laboratorios Esteve, Menarini, Mundipharma, Novartis, Rovi, Roxall, Sanofi, Stallergenes-Greer and Teva. The remaining authors declare that they have no competing interests.